Replies to post #21016 on Radient Pharmaceuticals Corporation fka RXPC

[dcspka]

b]Lets try another example

Lets talk about Amarantus and its "licensed" property, MANF. and its implications to be a Huge Benefit when it becomes part of the RXPC Takeover.

"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.... I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

Dr. Rubinfeld is one of the four original co-founders of Amgen.


Now who are we to believe whether that Amarantus is a worthy addition to Memory Dx and to the Provista/Rxpc Takeover?

Easy answer.